Evidence map›Paper›PMID 27334415›Full record

Trial reportBritish journal of clinical pharmacology2016

Exploring genetic and non-genetic risk factors for delayed graft function, acute and subclinical rejection in renal transplant recipients.

Dirk Jan A R Moes, Rogier R Press, Oliver Ackaert, Bart A Ploeger, Frederike J Bemelman, Cheikh Diack, Judith A M Wessels, Tahar van der Straaten, Meindert Danhof, Jan-Stephan F Sanders and 3 more

Open access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in British journal of clinical pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Interventions for BK virus infection in kidney transplant recipients.The Cochrane database of systematic reviews · 2024
    Pooled it
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Article
  7. Association of thePharmacogenomics and personalized medicine · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Dirk Jan A R MoesDepartment of Nephrology, Leiden University Medical Center, Leiden, The Netherlands.
Rogier R PressDepartment of Nephrology, Leiden University Medical Center, Leiden, The Netherlands.
Oliver AckaertLeiden Experts on Advanced Pharmacokinetics and Pharmacodynamics (LAP&P Consultants BV), Leiden, The Netherlands.
Bart A PloegerLeiden Academic Center for Drug Research (LACDR), Leiden, The Netherlands.
Frederike J BemelmanDepartment of Nephrology, Academic Medical Center Amsterdam, The Netherlands.
Cheikh DiackLeiden Experts on Advanced Pharmacokinetics and Pharmacodynamics (LAP&P Consultants BV), Leiden, The Netherlands.
Judith A M WesselsDepartment of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.
Tahar van der StraatenDepartment of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.
Meindert DanhofLeiden Academic Center for Drug Research (LACDR), Leiden, The Netherlands.
Jan-Stephan F SandersDepartment of Nephrology, University Medical Center Groningen, The Netherlands.
Jaap J Homan van der HeideDepartment of Nephrology, Academic Medical Center Amsterdam, The Netherlands.
Henk Jan GuchelaarDepartment of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.
Johan W de FijterDepartment of Nephrology, Leiden University Medical Center, Leiden, The Netherlands.
Leiden University Medical Center · NLPharmacoGenetics (China) · CNAcademic Medical Center · NLCentre for Human Drug Research · NLUniversity Medical Center Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThis study aimed at identifying pharmacological factors such as pharmacogenetics and drug exposure as new predictive biomarkers for delayed graft function (DGF), acute rejection (AR) and/or subclinical rejection (SCR).

methodsAdult renal transplant recipients (n = 361) on cyclosporine-based immunosuppression were followed for the first 6 months after transplantation. The incidence of DGF and AR were documented as well as the prevalence of SCR at 6 months in surveillance biopsies. Demographic, transplant-related factors, pharmacological and pharmacogenetic factors (ABCB1, CYP3A5, CYP3A4, CYP2C8, NR1I2, PPP3CA and PPP3CB) were analysed in a combined approach in relation to the occurrence of DGF, AR and prevalence of SCR at month 6 using a proportional odds model and time to event model.

resultsFourteen per cent of the patients experienced at least one clinical rejection episode and only DGF showed a significant effect on the time to AR. The incidence of DGF correlated with a deceased donor kidney transplant (27% vs. 0.6% of living donors). Pharmacogenetic factors were not associated with risk for DGF, AR or SCR. A deceased donor kidney and acute rejection history were the most important determinants for SCR, resulting in a 52% risk of SCR at 6 months (vs. 11% average). In a sub-analysis of the patients with AR, those treated with rejection treatment including ATG, significantly less frequent SCR was found in the 6-month biopsy (13% vs. 50%).

conclusionsTransplant-related factors remain the most important determinants of DGF, AR and SCR. Furthermore, rejection treatment with depleting antibodies effectively prevented SCR in 6-month surveillance biopsies.

Indexed as

PharmacogeneticsAdultAntibodiesBiomarkersBiopsyCyclosporineDelayed Graft FunctionGraft RejectionHumansImmunosuppressive AgentsIncidenceKidney TransplantationMaleMiddle AgedPrevalenceProspective StudiesAntibodiesBiomarkersCyclosporineImmunosuppressive AgentsAcute rejectionDelayed graft functionPharmacogeneticsPharmacometricsRenal transplantationSubclinical rejection

Identifiers

PMID27334415
PMCPMC4917801
OpenAlexW2330848779

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.